

Research group at the Tyndall National Institute got an article published on the use of up-converting nanoparticles

A research group at the Tyndall National Institute in Cork, Ireland, got an article published in Biomedical Optics Express titled "High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles". The research study uses Lumito's technology with up-converting nanoparticles (UCNPs).

The article examines the use of UCNPs to distinguish different levels of HER2 in CPA (control pellet arrays) and HER2-positive breast cancer tissue. The results demonstrate a good semi-quantitative tool for assessing HER2 in breast cancer tissues.

- It is very positive that our technology is being tested in different types of applications, and we are pleased that the results in the article are promising compared to traditional reference methods, comments CEO Mattias Lundin.

The article is published here: <https://opg.optica.org/boe/fulltext.cfm?uri=boe-15-2-900&id=545726>

For further information, please contact:

Mattias Lundin, CEO Lumito
E-mail: ml@lumito.se
Ph: +46 76 868 45 09

Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Research group at the Tyndall National Institute got an article published on the use of up-converting nanoparticles](#)